Malignant phase hypertension (MHT) is a relatively rare condition which affects <1% of people with essential hypertension and is often not recognized until a later stage in the disease process when clinical symptoms become apparent and patients are symptomatic. The true hallmark of MHT is fibrinoid arteriolar necrosis in many vascular beds but it is usually defined clinically as severe hypertension together with bilateral retinal hemorrhages and exudates, with or without papilledema on fundoscopy and retinal photography, and is associated with a grave prognosis if left untreated. [1] [2] [3] The incidence and prevalence of MHT does not appear to have diminished over time [4] [5] [6] although the prognosis of the disease has improved significantly. Before the disease was treated, almost 8 out of 10 patients were dead within 2 years 2,3 but with the advances in antihypertensive medications, recognition of the disease, and more aggressive blood pressure treatment and control, the 5-year survival rate from our cohort more than a decade ago was 74%. 7 The present study examines whether there has been a change in the demography and clinical characteristics and survival of patients presenting with MHT over the past four decades and examines the factors related to survival.
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Methods
The methods for this study have been described in detail elsewhere. 7 In summary, all patients attending the City Hospital, Birmingham from 1964 to 2006, with a diagnosis of MHT (International Classification of Diseases (ICD) codes, 8th revision code 400, 9th revision 401-405 with fourth digit 9, or 10th revision I10) were identified by the computerized hospital activity register and the specialist hypertension clinic. A specialist MHT clinic was founded at the City Hospital, Birmingham in 1977 (by D.G.B.) and a register to include all existing patients and new referrals was established and all patients were followed up. The hospital notes of each patient were interrogated and demographic and clinical data were collected for all 446 patients.
MHT was clinically defined as the presence of severe hypertension in association with bilateral retinopathy with hemorrhages, and/or cotton wool spots or exudates, with or without papilledema, detected on fundoscopy and retinal photography. 7 We excluded those patients with unilateral retinal features or papilledema only, and type 1 diabetics. For the articles Survival in Malignant Hypertensives purposes of these analyses, proteinuria was categorized as absent (nil or trace (<30 mg/dl)) or present (+ (30-99 mg/dl) or ≥++ (≥100 mg/dl)). Serum creatinine levels are presented as median (interquartile range (IQR)) and dichotomized around the median (<1.62 and ≥1.62 mg/dl or <142.9 and ≥143.0 µmol/l). Renal impairment was defined as serum creatinine >2.26 mg/dl (or 200 µmol/l). Evidence of left ventricular hypertrophy was defined based on Sokolow-Lyon electrocardiogram voltage criteria of an R wave in lead V6 ≥35 mm or the sum of the S wave in V1 plus R wave in V5 or V6 ≥35 mm.
The total number of person-years of observation was calculated from the date the patient was diagnosed with MHT until the 31 December 2006 or to the time of death. The overall mean follow-up blood pressure was calculated from the average blood pressure recorded in 5-year periods from the date of diagnosis to 31 December 2006 or death/lost to follow-up, with the exception of patients diagnosed after 2001. For these patients, the average of the available follow-up blood pressures was calculated. Five-year survival analyses included those patients whose vital status 5 years after MHT diagnosis was known, including patients diagnosed up to May 2004 but excluded those diagnosed after May 2004.
Statistical analysis. Statistical analysis was conducted using SPSS for Windows, version 14.0 (SPSS, Chicago, IL). All statistical tests were two-tailed, with P values ≤0.05 considered statistically significant. To test for differences in characteristics between the decade of MHT diagnosis and outcomes (alive or dead), categorical variables were assessed using χ 2 -tests; continuous variables were assessed using one-way analysis of variance and Tukey post hoc tests, with the exception of serum creatinine, which was assessed using the Mann-Whitney U-test. The survival analyses were confined to the 341 patients whose vital status on 31 December 2006 was known and who did not have proven glomerulonephritis, polycystic kidney disease, renal cell carcinoma, polyarteritis nodosa, systemic lupus erythematosus, and progressive systemic sclerosis (n = 24) at diagnosis, as the progression to end-stage renal failure or death may be related to these underlying diseases rather than to control or failure to control blood pressure. Each of the baseline demographic variables was entered individually into a Cox regression model to estimate the relative risk of death associated with covariates. In order to determine the independent predictors of mortality, all significant univariate predictors plus sex were entered together into a Cox regression model. However, given the collinearity between systolic blood pressure (SBP) and diastolic blood pressure (DBP), only follow-up SBP was entered in the final Cox regression model. Table 1 . There were no significant differences in the mean age at diagnosis over the 40-year period but there were significantly more men diagnosed with MHT prior to 1967 compared to women. There was a significant increase (P = 0.001) in the proportion of ethnic minorities (South-Asian and Afro-Caribbeans) among the MHT patients over the past 30 years.
There were no significant difference in mean SBP and DBP at presentation, except for a significantly higher DBP between 1967 and 1976 compared to all other time periods (all P values <0.05), with the exception of 1977-1986 (P = 0.31). Further, there was no significant difference in the number of antihypertensive medications people were receiving at the time of their MHT diagnosis over the past 40 years, with almost 75% of patients not receiving any antihypertensive therapy at presentation, and only 55 patients (12.9%) receiving two or more antihypertensives (data not shown).
There was a significant decrease in baseline median serum creatinine between 1967-1976 and 1987 onward: prior to 1967, the median serum creatinine level was similar to those diagnosed with MHT between 1977 and 1986. The proportion of people presenting with renal impairment was significantly higher prior to 1977. The severity of retinopathy (presence of grade 4 Keith-Wagener-Barker retinopathy) at presentation declined significantly after 1977, with between 55% and around two-thirds of patients presenting with hemorrhages, exudates, and papilledema, compared to almost 90% before 1976. There was also a significant decline in the presence of left ventricular hypertrophy among those diagnosed with MHT after 1976. There was also a reduction in the prevalence of smoking over time, but significant differences were only evident from 1987 onward. The severity of proteinuria decreased over time, with the exception of those diagnosed between 1997 and 2006 but there was a significant increase in the presence of hematuria among MHT patients diagnosed after 1967.
There was a significant decrease in both follow-up SBP and DBP over time. No significant differences were evident between <1967 and 1967-1976 for follow-up SBP or DBP (P = 0.58 and P = 0.94, respectively), but Tukey post hoc tests revealed significantly lower follow-up SBP and DBP for each subsequent decade compared to <1967 and 1967-1976 (all P < 0.0001). The only other significant difference in follow-up SBP was evident between 1977-1986 and 1997-2006 (P = 0.031). There were no further significant changes in follow-up DBP after 1977. Table 2 presents the underlying cause of hypertension for the whole MHT cohort (n = 446). More than half of the patients had essential hypertension, with almost one-quarter of the cohort having chronic renal impairment with no evidence of underlying renal disease, and only 6.1% of patients having preexisting conditions, such as glomerulonephritis, polycystic kidney disease, renal cell carcinoma, polyarteritis nodosa, systemic lupus erythematosus, or progressive systemic sclerosis, which may have lead to end-stage renal failure or death. The main causes of death were chronic renal failure (34.7%), stroke (19.8%), congestive cardiac failure (10.9%), coronary heart disease (10.4%), cancer (4.0%), and other causes (3.0%). The cause of death was unknown in 17.3%. Figure 1 presents the 5-year survival rate by decade of diagnosis and demonstrates a significant increase (P < 0.0001) in 5-year survival with each decade after 1976, from around one-third of patients diagnosed before 1977 to more than threequarters of patients diagnosed after 1977. The overall 5-year mortality rate was 34.6%, largely driven by those diagnosed prior to 1977. Table 2 ) likely to lead to end-stage renal failure and/or death (n = 341).
Those patients who survived were significantly younger at diagnosis than those who died (P < 0.0001). The mortality rate articles
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was similar among white-Europeans and African-Caribbeans, but significantly lower among South-Asians (P = 0.004).
Patients with higher median serum creatinine and those who smoked cigarettes at the time of diagnosis were more likely to die (both P values <0.0001). Those who survived also had lower follow-up SBP and DBP than those who died (both P values <0.0001). Decade of MHT diagnosis was also associated with survival. Those patients who were diagnosed with MHT from 1977 onward were more likely to survive than patients diagnosed before 1977. Interestingly, their baseline blood pressure was not predictive of survival.
Predictors of survival
Unadjusted Cox regression analyses for all MHT patients whose vital status on 31 December 2006 was known and who a These people were excluded from the survival analyses in tables 3 and 4, as the progression to end-stage renal failure/death may have been related to the progression of these diseases rather than the control or failure to control blood pressure.
Downloaded from https://academic.oup.com/ajh/article-abstract/22/11/1199/366392 by guest on 08 December 2018 articles
Survival in Malignant Hypertensives
did not have underlying causes of hypertension likely to lead to end-stage renal failure and/or death demonstrated that being younger, being diagnosed with MHT after 1977, with a lower baseline serum creatinine, being a nonsmoker at presentation, the absence of proteinuria, and lower follow-up SBP and DBP were associated with survival (see Table 4 ). In multivariate analyses adjusting for age, sex, decade of diagnosis, baseline serum creatinine and smoking status, presence of proteinuria, and follow-up SBP, only age, decade of diagnosis, baseline serum creatinine, and follow-up SBP were independent predictors of survival (all P values <0.0001).
discussion
The current study of 446 patients collected over the past 40 years, with a median (IQR) 103.4 (31.3-251.2) months of follow-up, represents the largest series of MHT patients in the world literature. The demography of the MHT population has not changed dramatically over the past 40 years, nor has the number of new cases of MHT per year. However, the 5-year survival rate of patients in our cohort has improved significantly over this period, from one in three diagnosed prior to 1976 to nine out of ten patients presenting between 1997 and 2006. The best predictors of survival in this cohort were age, decade of MHT diagnosis, baseline serum creatinine, and follow-up SBP, with younger patients, those diagnosed from 1977 onward, those with lower baseline serum creatinine levels, and those with lower follow-up SBP being more likely to survive.
incidence of Mht
The majority of the world literature on MHT has come from our cohort of patients published over the past 30 years (e.g., refs. 4,7-9), although there are a few other reported series of MHT populations in the literature, 5,6,10-13 only two others have examined the incidence and outcome of MHT in recent years. 5, 6 Almost a decade ago a meeting on hypertension for the Department of Veterans Affairs suggested that MHT was a "disappearing disease" 14 but two European cohorts demonstrate a fairly stable incidence of MHT, of 2-3 cases per 100,000 head of population 5, 6 over the past 30 years or so, and the present study 4,9 reports 2-3 new cases of MHT per 100,000 head of population per year. The demography of the disease has not altered over the 40 years of follow-up, with no significant differences in the mean age at diagnosis, but a slight predominance in men. There was a significant increase in the proportion of ethnic minorities (South-Asian and Afro-Caribbeans) and a significant decrease in white-Europeans (P = 0.001) among the MHT patients over the past 40 years. This may be a reflection of immigration to the United Kingdom during the 1960s onward. Data from the 1981, 1991, and 2001 census 15 for the West Midlands demonstrate the changing ethnic distribution of people in Birmingham and Sandwell, with the 1991 census data showing that the West Birmingham population comprised 66% white-European, 12% African-Caribbean, and 22% South-Asian.
changing clinical presentation of Mht
More than half of the cohort had essential hypertension (54.3%), with almost one-quarter of the cohort having chronic renal impairment with no evidence of underlying renal disease. However, it was not our policy to perform renal biopsies or renal angiograms if the blood pressure was coming under control and the renal function was improving, so we cannot exclude People with glomerulonephritis, polycystic kidney disease, renal cell carcinoma, polyarteritis nodosa, systemic lupus erythematosus, and progressive systemic sclerosis were excluded from the survival analyses as the progression to end-stage renal failure/death may have been related to the progression of these diseases rather than the control or failure to control blood pressure. DBP, diastolic blood pressure; LVH, left ventricular hypertrophy; MHT, malignant phase hypertension; SBP, systolic blood pressure. a Adjusted for age, sex, ethnicity, decade of MHT diagnosis, proteinuria, baseline creatinine and smoking status, and follow-up SBP.
articles
Survival in Malignant Hypertensives
the possibility that some patients with renal impairment may have had underlying glomerulonephritis or renal artery stenosis. However, the present study examined the outcomes in the whole cohort excluding those with an underlying cause of their hypertension that may have progressed to end-stage renal failure or death and for whom vital status was known (n = 341). Those who were younger, not white, nonsmoker at baseline, with lower median serum creatinine and no evidence of proteinuria at presentation, diagnosed from 1977 onward, and those with lower follow-up SBP, being more likely to survive. However, there have been some significant changes in the clinical presentation of the disease over the past four decades of note. Although there were no differences in the SBP and DBP at diagnosis over time, there were significant decreases in median serum creatinine, severity of proteinuria and retinopathy, and evidence of left ventricular hypertrophy in patients over time, particularly from 1977 onward. Scarpelli and colleagues also confirm a significant reduction in severity of retinopathy at presentation from 1974 to 2000. 16 This suggests that MHT may have been diagnosed at an earlier stage from 1977 onward, before the onset of renal impairment and hypertensive heart disease, which may help to explain the significant improvement in 5-year survival rate evident after this time. Indeed, a specialist hypertension clinic was established in 1977 and these patients were routinely followed up by a physician with a specialist interest in MHT (D.G.B.).
Mortality and Mht
Although the incidence of MHT is not declining, there have been substantial decreases in mortality rates since MHT was first identified. Prior to the advent of antihypertensive medication, the 5-year survival rate of patients with MHT was 1%. 2, 3 However, survival rates from MHT continued to improve over the next 30 years with the development of new classes of antihypertensives. 1, 12, 17 Indeed, the present study demonstrates a massive improvement in 5-year survival by decade of diagnosis from 1964 to 2006, particularly from 1977 onward. The overall 5-year survival rate in our cohort was 66%, a finding similar to other European cohorts. 5, 6, 13 The best independent predictors of overall survival were age, decade of MHT diagnosis, serum creatinine level at presentation, and follow-up SBP. The present study demonstrates that a dedicated MHT service, tighter blood pressure control, and availability of better antihypertensive drugs has translated into a vast improvement in 5-year survival from the disease. MHT is not a "disappearing disease, " with a relatively stable number of 2-3 new cases of MHT per year but significantly increased survival rates due to earlier detection, tighter blood pressure control and lower blood pressure targets, better choice of antihypertensive drugs, and the availability of hemodialysis and renal transplantation.
